The estimated Net Worth of Robert Martell is at least $900 Tysiąc dollars as of 23 January 2019. Robert Martell owns over 5,500 units of Curis Inc stock worth over $117,438 and over the last 13 years he sold CRIS stock worth over $5,885. In addition, he makes $776,494 as Head - Research and Development at Curis Inc.
Robert has made over 1 trades of the Curis Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 5,500 units of CRIS stock worth $5,885 on 23 January 2019.
The largest trade he's ever made was selling 5,500 units of Curis Inc stock on 23 January 2019 worth over $5,885. On average, Robert trades about 367 units every 0 days since 2011. As of 23 January 2019 he still owns at least 23,027 units of Curis Inc stock.
You can see the complete history of Robert Martell stock trades at the bottom of the page.
Dr. Robert E. Martell M.D. Ph.D. serves as Head - Research and Development of the Company. He has served on board since September 2011. Dr. Martell is a practicing medical oncologist at Tufts Medical Center and has served as Chief Medical Officer at Tesaro, Inc., a biopharmaceutical company, since September 2012. Dr. Martell is also an Adjunct Associate Professor of Medicine at the Tufts University School of Medicine, a position he has held since September 2012. From September 2009 to September 2012, Dr. Martell was employed at Tufts Medical Center, serving as both the Director of the Neely Center for Clinical Cancer Research, overseeing oncology clinical research, and the Leader of the Cancer Center’s Program in Experimental Therapeutics, where he was responsible for developing the center’s phase I oncology clinical development program. From September 2009 to September of 2012, Dr. Martell was also an Associate Professor of Medicine at the Tufts University School of Medicine. From May 2005 to July 2009, Dr. Martell served as Vice President and Chief Medical Officer of MethylGene, a publicly-traded biotechnology company focused on the development of cancer therapeutics. From November 2002 to May 2005, Dr. Martell also served as Director of Oncology Global Clinical Research at Bristol-Myers Squibb Company, a biopharmaceutical company. From July 2001 to May 2005, Dr. Martell served concurrently as Assistant Clinical Professor of Oncology at Yale University School of Medicine and Staff Physician at the Veterans Affairs hospital. From July 2000 to October 2002, Dr. Martell worked at Bayer Corporation, Pharmaceutical Division, where he oversaw phase I and phase II clinical studies. Dr. Martell received a B.A. in chemistry from Kalamazoo College, a Ph.D. in pharmacology from the University of Michigan, and an M.D. from Wayne State University.
As the Head - Research and Development of Curis Inc, the total compensation of Robert Martell at Curis Inc is $776,494. There are 2 executives at Curis Inc getting paid more, with James Dentzer having the highest compensation of $1,557,770.
Robert Martell is 57, he's been the Head - Research and Development of Curis Inc since 2018. There are 6 older and 4 younger executives at Curis Inc. The oldest executive at Curis Inc is Martyn Greenacre, 78, who is the Independent Chairman of the Board.
Over the last 24 years, insiders at Curis Inc have traded over $10,321,234 worth of Curis Inc stock and bought 10,678,594 units worth $25,596,192 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Discovery Technologies Ltd ... oraz James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of $811,553. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth $17,160.
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
Curis Inc executives and other stock owners filed with the SEC include: